BioNTech’s ASCO Conundrum: Lung Cancer Data Shines, But Gotistobart’s Dose Paradox Clouds the Picture
02.06.2026 - 17:04:13 | boerse-global.de
BioNTech wrapped up this year’s American Society of Clinical Oncology (ASCO) meeting in Chicago with a pipeline that generated both applause and head-scratching. The Mainz-based cancer specialist unveiled encouraging late-stage data and locked in a fresh analyst upgrade, yet its share price refused to budge. The stock hovered around €78.20 on Tuesday, roughly 23% below its 52-week high of €101.90 and nearly 21% lower than where it traded a year ago – despite a $1 billion buyback programme and a growing roster of clinical catalysts.
The most puzzling takeaway came from gotistobart (BNT316/ONC-392), a CTLA-4 targeting antibody co-developed with OncoC4. Interim results from the Phase 2 PRESERVE-004 study in heavily pretreated, platinum-resistant ovarian cancer patients showed durable antitumour activity and clinically meaningful overall survival rates. But the dosing pattern defied logic: patients receiving a low dose of 1 mg/kg achieved a median overall survival of 18.9 months, while those given 2 mg/kg clocked only 8.3 months. Rates of dose interruptions due to side effects ran at 33% in the low-dose group versus 38% in the high-dose arm, and treatment discontinuation stood at 15% and 31% respectively. BioNTech described the safety profile as manageable, but the asymmetry between dosage and efficacy remains a problem the company must solve before it can outline any specific development path in ovarian cancer. No such plan has been announced.
Elsewhere on the ASCO podium, BioNTech’s Pumitamig (BNT327) stole a brighter spotlight. This PD-L1/VEGF-A bispecific antibody, evaluated together with Bristol Myers Squibb in the Phase 2 ROSETTA Lung-02 trial for advanced non-small cell lung cancer (NSCLC), delivered response rates that turned heads. In non-squamous patients the confirmed objective response rate reached 57.1%; in squamous patients it hit 68.4%. For those with a tumour proportion score of 50% or higher, the response rate touched 100%. Disease control across the entire evaluable cohort was also 100%. On the safety side, grade 3 or higher adverse events occurred in 48.8% of patients, of which 23.3% were attributed to Pumitamig itself. After a median follow-up of 9.0 months, 9.3% of patients discontinued treatment because of side effects.
Should investors sell immediately? Or is it worth buying BioNTech?
Beyond those two headline candidates, BioNTech showcased a growing antibody-drug conjugate (ADC) pipeline that includes HER3-directed BNT326/YL202, B7H3-directed BNT324/DB-1311 in metastatic castration-resistant prostate cancer, and HER2-directed Trastuzumab Pamirtecan in recurrent endometrial carcinoma. The company plans to launch six further Phase 3 trials in 2026, bringing the total to 15, and expects seven late-stage data readouts over the course of the year. A regulatory filing for Trastuzumab Pamirtecan in HER2-positive endometrial cancer is targeted before year-end.
Financially, BioNTech remains well cushioned, sitting on €16.8 billion in cash and equivalents as of March 31, 2026. First-quarter revenue slipped to €118.1 million from €182.8 million a year earlier, and the net loss widened to €531.9 million. Management’s full-year guidance calls for revenue of €2.0 billion to €2.3 billion and R&D spending of €2.2 billion to €2.5 billion. The $1 billion buyback – covering roughly 4.2% of outstanding shares – signals the board’s confidence in the oncology pivot, and institutional investors have been building positions.
Analysts are taking note. UBS upgraded BioNTech from Neutral to Buy shortly before ASCO ended, lifting its price target from $117 to $135. Jefferies maintained its Buy recommendation despite the stock’s 3.9% slide on June 1. The consensus among 19 analysts stands at a Moderate Buy with an average target of $129.56, ranging from $94 to $158 – well above the current share price in both dollar and euro terms.
The critical question now is whether the dose puzzle around gotistobart can be resolved into a clear development pathway or whether it will slow momentum for a candidate that otherwise showed real clinical benefit. With Phase 3 results across the pipeline not expected until the second half of the decade, BioNTech must convince the market that its transformation from Covid vaccine maker to oncology powerhouse is on track – and that the anomalies on the data table are solvable, not structural.
Ad
BioNTech Stock: New Analysis - 2 June
Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
